Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29208044 | 0.85 | SSTR4 (0.46) | SSTR4MAPK1TRPV1BRD4CREBBP | |
| SCHEMBL30812977 | 0.84 | POLB (0.44) | SSTR4MAPK1TRPV1KDM4EGAA | |
| SCHEMBL9785817 | 0.84 | POLB (0.44) | SSTR4MAPK1TRPV1KDM4EGAA | |
| SCHEMBL7300865 | 0.81 | SSTR4 (0.42) | SSTR4MAPK1TRPV1BRD4CREBBP | |
| SCHEMBL24262284 | 0.79 | SSTR4 (0.38) | SSTR4MAPK1BRD4CREBBPKDM4E | |
| SCHEMBL27720908 | 0.78 | SSTR4 (0.40) | SSTR4MAPK1KMT2AGAASMN1; SMN2 | |
| SCHEMBL2740802 | 0.76 | SSTR4 (0.41) | SSTR4MAPK1KMT2AKDM4EGAA | |
| SCHEMBL27346326 | 0.76 | SSTR4 (0.46) | SSTR4KMT2AGAA | |
| SCHEMBL13444800 | 0.75 | ITGB2 (0.41) | SSTR4MAPK1SMN1; SMN2 | |
| SCHEMBL2583594 | 0.75 | BCHE (0.39) | BCHEMAPK1ACHEGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738064-B2 | Chiral α-amino tertiary boronic esters | PURDUE RESEARCH FOUNDATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200079799-A1 | Novel Chiral Alfa-Amino Tertiary Boronic Esters | PURDUE RESEARCH FOUNDATION (US) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079799-A1 | Novel Chiral Alfa-Amino Tertiary Boronic Esters | HBB, BCAT1, BCAT2 | SSTR4 218/4885BCHE 11/4885MAPK1 3580/4885 |
| US-10738064-B2 | Chiral α-amino tertiary boronic esters | HBB, BCAT1, BCAT2 | SSTR4 167/4885BCHE 11/4885MAPK1 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.